These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30678526)

  • 1. Reducing Uncertainty in EQ-5D Value Sets: The Role of Spatial Correlation.
    Shams S; Pullenayegum E
    Med Decis Making; 2019 Feb; 39(2):91-99. PubMed ID: 30678526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach.
    Pullenayegum EM; Chan KK; Xie F
    Med Decis Making; 2016 Feb; 36(2):223-33. PubMed ID: 26139449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Underestimation of Variance of Predicted Health Utilities Derived from Multiattribute Utility Instruments.
    Chan KK; Xie F; Willan AR; Pullenayegum EM
    Med Decis Making; 2017 Apr; 37(3):262-272. PubMed ID: 27216582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creating a Multiply Imputed Value Set for the EQ-5D-5L in Canada: State-Level Misspecification Terms Are Needed to Characterize Parameter Uncertainty Correctly.
    Tsui TCO; Chan KKW; Xie F; Pullenayegum EM
    Med Decis Making; 2024 May; 44(4):405-414. PubMed ID: 38591189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capturing Valuation Study Sampling Uncertainty in the Estimation of Health State Utility Values Using the EQ-5D-3L.
    Poulimenos S; Round J; Baio G
    Med Decis Making; 2024 May; 44(4):393-404. PubMed ID: 38584481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian Models with Spatial Correlation Improve the Precision of EQ-5D-5L Value Sets.
    Che M; Xie F; Thomas S; Pullenayegum E
    Med Decis Making; 2023 Jul; 43(5):587-594. PubMed ID: 37243474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conducting EQ-5D Valuation Studies in Resource-Constrained Countries: The Potential Use of Shrinkage Estimators to Reduce Sample Size.
    Chan KKW; Xie F; Willan AR; Pullenayegum EM
    Med Decis Making; 2018 Jan; 38(1):26-33. PubMed ID: 28823185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and sample size considerations for valuation studies of multi-attribute utility instruments.
    Shams S; Pullenayegum E
    Stat Med; 2020 Oct; 39(23):3074-3104. PubMed ID: 32706130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Less Is More: Cross-Validation Testing of Simplified Nonlinear Regression Model Specifications for EQ-5D-5L Health State Values.
    Rand-Hendriksen K; Ramos-Goñi JM; Augestad LA; Luo N
    Value Health; 2017; 20(7):945-952. PubMed ID: 28712624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of United States and United Kingdom EQ-5D health states valuations using a nonparametric Bayesian method.
    Kharroubi SA; O'Hagan A; Brazier JE
    Stat Med; 2010 Jul; 29(15):1622-34. PubMed ID: 20209481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
    Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
    Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of FACT- and EQ-5D-based utility scores in cancer.
    Pickard AS; Ray S; Ganguli A; Cella D
    Value Health; 2012; 15(2):305-11. PubMed ID: 22433762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Between-country heterogeneity in EQ-5D-3L scoring algorithms: how much is due to differences in health state selection?
    Pullenayegum EM; Perampaladas K; Gaebel K; Doble B; Xie F
    Eur J Health Econ; 2015 Nov; 16(8):847-55. PubMed ID: 25252970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selecting Health States for EQ-5D-3L Valuation Studies: Statistical Considerations Matter.
    Yang Z; Luo N; Bonsel G; Busschbach J; Stolk E
    Value Health; 2018 Apr; 21(4):456-461. PubMed ID: 29680103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms.
    Woodcock F; Doble B;
    Med Decis Making; 2018 Nov; 38(8):954-967. PubMed ID: 30226101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the Beck Depression Inventory to the EQ-5D-3L in Patients with Depressive Disorders.
    Grochtdreis T; Brettschneider C; Hajek A; Schierz K; Hoyer J; Koenig HH
    J Ment Health Policy Econ; 2016 Jun; 19(2):79-89. PubMed ID: 27453455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Importance of Accounting for Parameter Uncertainty in SF-6D Value Sets and Its Impact on Studies that Use the SF-6D to Measure Health Utility.
    Kharroubi SA; Beyh Y; Abdul Fattah E; Young T
    Int J Environ Res Public Health; 2020 Jun; 17(11):. PubMed ID: 32498412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
    Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
    Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
    Doble B; Lorgelly P
    Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.